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Women are more resistant to hepatocellular carcinoma (HCC) than
men despite equal exposure to major risk factors, such as hepatitis
B or C virus infection. Female resistance is hormone-dependent, as
evidenced by the sharp increase in HCC incidence in postmeno-
pausal women who do not take hormone replacement therapy. In
rodent models sex-dimorphic HCC phenotypes are pituitary-de-
pendent, suggesting that sex hormones act via the gonadal-
hypophyseal axis. We found that the estrogen-responsive pitui-
tary hormone prolactin (PRL), signaling through hepatocyte-pre-
dominant short-form prolactin receptors (PRLR-S), constrained TNF
receptor-associated factor (TRAF)-dependent innate immune
responses invoked by IL-1β, TNF-α, and LPS/Toll-like receptor 4
(TLR4), but not TRIF-dependent poly(I:C)/TLR3. PRL ubiquitinated
and accelerated poststimulatory decay of a “trafasome” comprised
of IRAK1, TRAF6, and MAP3K proteins, abrogating downstream
activation of c-Myc–interacting pathways, including PI3K/AKT,
mTORC1, p38 MAPK, and NF-κB. Consistent with this finding, we
documented exaggerated male liver responses to immune stimuli in
mice and humans. Tumor promotion through, but regulation above,
the level of c-Myc was demonstrated by sex-independent HCC erup-
tion in Alb-Myc transgenic mice. PRL deficiency accelerated liver car-
cinogenesis in Prl−/− mice of both sexes. Conversely, pharmacologic
PRL mobilization using the dopamine D2 receptor antagonist dom-
peridone prevented HCC in tumor-prone C3H/HeN males. Viewed
together, our results demonstrate that PRL constrains tumor-promot-
ing liver inflammation by inhibiting MAP3K-dependent activation of
c-Myc at the level of the trafasome. PRL-targeted therapy may hold
promise for reducing the burden of liver cancer in high-risk men
and women.
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Liver cancer is the third leading cause of cancer mortalityworldwide, and the fastest increasing cancer in the United
States (1). Despite equal exposure to major risk factors, such as
infection with hepatitis B or C virus, men develop hepatocellular
carcinoma (HCC) more than twice as often as women (1). Pro-
tection in women is hormone-dependent, as evidenced by the sharp
rise in female liver cancer incidence following menopause (2).
Hormone replacement therapy (HRT) in postmenopausal women
restores HCC resistance (3). Estrogen (17β-estradiol; E2) has been
shown to contribute directly to liver tumor inhibition through
effects on nonparenchymal hepatic immune cells (4, 5). However,
in rodent models the pituitary gland is indispensable to maintain
sex-dependent HCC phenotypes (6), suggesting that sex hormones
act via the gonadal-hypophyseal axis. Prolactin (PRL) is an E2-
responsive pituitary hormone expressed at higher levels in females
than males (7). Here, we show that PRL mitigates TNF receptor-
associated factor (TRAF)-mediated innate immune responses in
hepatocytes, preventing tumor-promoting activation of the liver
proto-oncogene c-Myc through multiple MAP3K-dependent
pathways, including PI3K/AKT, mechanistic target of rapamycin
(mTOR) complex 1 (mTORC1), p38 MAPK, and NF-κB. This
mechanism may contribute to HCC resistance in women.
Results
Short-Form Prolactin Receptor Mediates Liver Signaling. The pro-
lactin receptor (PRLR) has multiple splice variants with tissue-
specific expression (8). Long-form PRLR (PRLR-L) is the primary
receptor in breast and most other tissues, where it functions in
part through STAT5 (9). In contrast, short-form PRLR (PRLR-S)
does not meaningfully activate STAT5 or other PRLR-L pathways
(10). In female reproductive tissues, the proportion of long:
short-form receptor varies depending on hormonal fluctuations,
whereas the liver maintains a constant preference for PRLR-S
(11–13). In agreement with reports elsewhere (8), we found in
mammary tissue and cells that 85–90% of total PRLR mRNA
was PRLR-L, whereas in mouse and human liver tissue the vast
majority was PRLR-S (Fig. S1A). Murine Hepa 1–6 and AML12
liver cells retained in vivo liver preference for PRLR-S over
PRLR-L. In contrast, human liver cell lines, including HCC-
derived Hep3B and HuH7, immortalized hepatocyte subclone
PH5CH8, and hepatoblastoma-origin HepG2 and HuH6
exhibited variable total PRLR but a universal preference for
PRLR-L over PRLR-S (Fig. S1B; all liver cell line origins are
depicted in Table S1). Our findings correlated well with a pub-
lished microarray comparison of PRLR expression in human
liver cell lines (14). Based on the above observations, we chose
the murine liver cell lines Hepa 1–6 and AML12, except where
noted for the functional PRL studies below. There are at least
three known splice variants of PRLR-S in mice and two in
humans (15, 16). In mice, we found that variant S3 comprised
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>90% of all PRLR-S (Fig. S1C). In human liver, PRLR-S1a was
significantly more abundant than isoform S1b. We confirmed
site-specific PRLR isoform expression at the protein level by
Western blot (Fig. S1D). To determine the impact of pituitary
hormones on STAT5 and MAPK signaling, we withdrew serum
from Hepa 1–6 cells and subsequently reintroduced PRL or
growth hormone. Phosphorylation of STAT5 and ERK1/2 was
not affected by any treatment in these cells (Fig. S1E), whereas
serum starvation activated the stress-associated protein kinase
p38 MAPK. Intriguingly, PRL but not growth hormone de-
creased p38 MAPK phosphorylation to levels found in un-
stressed cells grown with serum. Inhibition of MAP kinases
including p38 MAPK was shown elsewhere to be a feature of
PRLR-S but not PRLR-L signaling (17). These data highlight
PRLR-S as the primary prolactin receptor in differentiated
hepatocytes, and show that PRL exposure constrains at least one
cell stress-associated pathway.
PRL Inhibits IL-1β Induction of p38 MAPK, NF-κB, and AKT. IL-1β is an
injury-associated innate immune cytokine implicated in tumor-
promoting liver inflammation (18). To begin our search for PRL-
sensitive innate immune pathways in hepatocytes, we exposed
Hepa 1–6 and AML12 cells with or without PRL preconditioning
to recombinant murine IL-1β. In addition to p38 MAPK, we
found that PRL exposure decreased IL-1β–induced phosphory-
lation of AKT and NF-κB p65/RelA, but not ERK1/2 or JNK
(Fig. 1A). At the message level, PRL inhibited transcription of
important murine acute-phase response (APR) genes in IL-1β–
challenged hepatocytes, including serum amyloid A1 and A3,
lipocalin-2, and orosomucoid (α-1-acid glycoprotein) (Fig. 1B).
The Toll-like receptor (TLR)4 ligand LPS also invoked immune
responses in these cells (Fig. S2A). In a time-course study, he-
patocyte preconditioning with PRL for 1 h significantly reduced
IL-1β– and LPS-induced target phosphorylation, although 2 h
was required for maximal inhibition; this effect was durable up to
8 h (Fig. S2B). Because 1–2 h of PRL incubation was required to
achieve maximal inhibition, we tested whether PRL interruption
of IL-1β responses required de novo transcription. However, by
microarray we identified few PRL-inducible genes and no com-
mon gene sets shared between Hepa 1–6 and AML12 cells;
moreover, we observed no effect by the transcription inhibitor
actinomycin D on PRL-sensitive gene expression in either
cell line [National Center for Biotechnology Information Gene
Expression Omnibus (GEO) SuperSeries accession no. GSE55669].
Viewed together, these data suggest that PRL inhibits IL-1β phos-
phorylation of p38 MAPK, NF-κB, and AKT in hepatocytes in
a transcription-independent manner.
PRL Restricts TLR4 and TNF-α but Not TLR3 Signaling. To extend our
investigation of innate immune pathways susceptible to PRL
interruption, we challenged hepatocytes with the TLR3 ligand
and dsRNA mimetic poly(I:C), TNF receptor-1 (TNFR1) ligand
TNF-α, and LPS using NF-κB p65/RelA phosphorylation as
a readout. PRL preconditioning reduced NF-κB activation by
LPS and TNF-α but not poly(I:C) (Fig. S2C). In agreement with
this, PRL-preconditioned hepatocytes showed muted APR gene
expression in the face of LPS challenge, whereas there was no
impact by PRL on poly(I:C)-induced APR or TLR3-specific IFN
pathway-associated gene transcription (Fig. S2D). Our aggregate
findings indicate that PRL dampens hepatocellular immune
responses that signal through IL1R, TLR4, and TNFR1, but
not TLR3.
Female Mouse Liver Constrains IL-1β Responses. In humans and in
rodent models, females are more resistant to chronic progressive
hepatitis and HCC than males (1, 3, 19, 20). To determine
whether PRL-sensitive innate immune pathways contribute to
this sexual dimorphism, we challenged male and female C3H/
HeN mice with IL-1β or poly(I:C). Mirroring results from PRL-
preconditioned hepatocytes, females challenged with IL-1β
showed reduced phosphorylation of p38 MAPK, NF-κB p65/
RelA, and AKT, but not ERK1/2, JNK, or STAT3 compared
with males (Fig. 1C). Also reflecting in vitro results, there were
no consistent sex-dependent differences in liver gene induction
in mice challenged with poly(I:C) (Fig. S2E). We found by
microarray that message levels of IL-1β–inducible APR genes in
vivo did not exhibit as clear a sex difference as PRL-precondi-
tioned hepatocyte cultures (GEO accession no. GSE55669). This
result was likely in part because of sex-independent IL-1β in-
duction of IL-6 (increased >100-fold both sexes) from Küppfer
cell macrophages in intact liver; significant redundancy is known
to exist between IL-1β– and IL-6–inducible APR pathways (21).
APR genes notwithstanding, the impact of IL-1β on transcription
of many important inflammatory, cell stress, and growth-associ-
ated gene products was muted in female mouse liver, including
heme oxygenase-1, early growth response-1, IL-17 receptor-α,
inducible nitric oxide synthase (iNOS), TGF-α, VEGF-α, and
c-Myc (Fig. 1D). In agreement with a prior study from our group
(19), we also observed overrepresentation of sexually dimorphic
liver genes among those altered by IL-1β, including feminine
genes Cyp2b9, Cyp2b13, Cyp4a10, Cyp4a14, and Sult2a3, as well
as masculine genes C6, Cyp4a12, Elovl3, Lcn13, and Spink6
(GEO accession no. GSE55669). Thus, loss of transcriptional
regulation of many sex-dependent genes (a process we previously
termed “liver-gender disruption”), is an early event in the di-
chotomous progression of chronic liver disease (19, 22). In
summary, in vivo IL-1β challenge results mirrored those ob-
served in vitro, and confirmed that immune induction of tumor-
promoting metabolic, stress and cell proliferation pathways
exhibits sexual dimorphism at an early stage.
Men Have a Proinflammatory Hepatic Microenvironment. To de-
termine whether sex-dependent proinflammatory liver pheno-
types extend to humans, we acquired tissue specimens from
seven adult women and men without evidence of primary liver
disease (Table S2; donor inclusion criteria in SI Materials and
Methods) and performed genome-wide expression analysis (GEO
accession no. GSE55669). Heat maps (Fig. 2A) and hierarchal
clustering readily differentiated male from female liver. Using
additional conservative filtering criteria (SI Materials and Meth-
ods), we identified 131 female-predominant and 445 male-pre-
dominant unique transcripts (Table S3). We confirmed sex-
specificity of selected masculine and feminine liver genes by
quantitative RT-PCR (qRT-PCR) (Fig. 2B). Of interest, while
Fig. 1. Prolactin/female sex constrains hepatocellular IL-1β responses in
vitro and in vivo. (A) PRL preconditioning in AML12 hepatocytes reduces
IL-1β phosphorylation of p38 MAPK, NF-κB p65/RelA, and AKT. (B) IL-1β in-
duction of APR genes is diminished in PRL-preconditioned hepatocytes. (C)
Decreased phosphorylation of p38 MAPK, NF-κB p65/RelA, and AKT but not
STAT3, JNK, or ERK1/2 in IL-1β–challenged female versus male mouse liver.
(D) Muted induction of inflammatory and tumor-associated genes in IL-1β–
challenged females versus males. Data are expressed as mean ± SEM (n = 5
per sex); *P < 0.05, Student t test.
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analyzing the masculine gene set we noted a large number of
canonical APR and inflammation-associated genes as well as
several proto-oncogenes, including c-Myc (Fig. 2C). Indeed, of
the top six biological function categories distinguishing male
from female liver, five were associated with cancer or inflam-
matory disease; the other was reproduction (Fig. 2D). Whereas
our study could not control for lifestyle factors or correlate se-
rum hormone levels, gene expression results suggest that men—
even those without clinically evident liver disease—maintain
more of a proinflammatory hepatic microenvironment than
women. If our animal model data are indicative, then a relative
inability of the human male liver to constrain minor immune
stimuli may serve as a bellwether of increased sensitivity to tu-
mor-promoting inflammation. This finding agrees with the
known higher risk of men with chronic viral hepatitis to progress
to cirrhosis or HCC (1, 3).
PRL Interrupts IL-1β Upstream of p38 MAPK and AKT. p38 MAPK,
NF-κB, and AKT have both overlapping and distinct immune
signaling functions. To begin to understand how these pathways
cross-talk and how PRL might impact them in the liver, we ap-
plied a variety of kinase and phosphatase inhibitors to cultured
hepatocytes. However, in our hands the impact of most inhibitors
on IL-1β ± PRL signaling was context- and cell line-dependent
(Tables S4 and S5). Because the dual-specificity phosphatase
(DUSP) DUPD1 previously was implicated in PRLR-S–medi-
ated inhibition of p38 MAPK and ERK1/2 in PRLR-L–deficient
mouse reproductive tissues (17), we were particularly interested
in the potential role of DUPD1 in hepatocyte PRL signaling.
However, none of the kinase or phosphatase inhibitors that
target p38 MAPK, including the DUSP inhibitor NSC 95397,
gave consistent results between mouse and human cell lines
(Table S5). Moreover, neither PRL nor NSC 95397 impacted
ERK1/2 phosphorylation, suggesting that a mechanism besides
or in addition to DUPD1 mediates PRLR-S activity in hep-
atocytes. In contrast, the PI3K inhibitors wortmannin and
LY294002 consistently abolished AKT phosphorylation, in-
dicating PI3K dependence (Fig. S3A). Using specific inhibitors,
we further found that IL-1β activated PI3K/AKT and p38 MAPK
pathways independent of one another (Fig. S3B), suggesting that
PRL intervenes at a common upstream site. In genetically
engineered mice, constitutive liver activation either of PI3K/
AKT or its downstream target mTORC1 results in HCC (23). To
determine whether PRL interruption of PI3K/AKT also obviates
mTORC1, we evaluated IL-1β–inducible phosphorylation of
mTORC1 components, including mTOR, glycogen synthase ki-
nase 3 beta (GSK-3β), p70 S6-kinase (S6K), and eukaryotic
translation initiation factor 4E binding protein-1 (4E-BP1). Im-
portantly, PRL interruption of PI3K/AKT also abrogated phos-
phorylation of mTOR and 4E-BP1 (Fig. 3A). We were unable to
detect phospho-specific GSK-3β or S6K under any of our ex-
perimental conditions. Taken together, our results demonstrate
that PRL interrupts IL-1β signaling at a node upstream of p38
MAPK and PI3K, and reveal that constraint of PI3K/AKT also
alleviates downstream mTORC1.
PRL Targets Are MAP3K- but Not Ras-Dependent. Ras is a well-
characterized oncogene that acts in part through PI3K/AKT,
whereas MAP3K enzymes (notably TAK1) may simultaneously
target NF-κB and p38 MAPK (24). To clarify the role of these
pathways in our system, we used the Ras inhibitor manumycin
and MAP3K inhibitor 5(Z)-7-oxozeaenol. Unexpectedly, we
discovered that Ras inhibition increased phosphorylation of all
IL-1β targets except NF-κB (Fig. 3B). In contrast, the MAP3K
inhibitor abolished endogenous and IL-1β–inducible phosphor-
ylation of all targets (except some residual Ras-dependent
NF-κB). At nanomolar concentrations, 5(Z)-7-oxozeaenol is a
TAK1-specific antagonist; however, at the 10-μM concentration
we used it inhibits other MAP3K (25). We found that decreasing
the concentration of 5(Z)-7-oxozeaenol below 10 μM diminished
inhibition of IL-1β target activation in a dose-dependent fashion
(Fig. S3C). Therefore, one or more MAP3K besides or in ad-
dition to TAK1 must transmit PRL-sensitive IL-1β signals in
hepatocytes. Further work will be required to identify which of
the >20 MAP3K participate in PRL-sensitive hepatocellular
signaling (26). Nevertheless, our data show that innate immune
pathways interrupted by PRL are MAP3K-dependent.
PRL Primes “Trafasome” for Poststimulatory Degradation. Based on
the results above, we directed our search for molecular PRL
targets toward MAP3K-dependent pathways shared by IL1R,
TLR4, and TNFR1, but not TLR3. Of note, all of the PRL-
sensitive pathways listed above, but not PRL-insensitive TLR3,
involve TRAF proteins. This finding is significant because TRAF
Fig. 2. Adult men without primary liver disease maintain a more proin-
flammatory hepatic microenvironment than women. (A) Heat map demon-
strates clear distinction between male and female human liver (n = 7 per
sex). (B) qRT-PCR confirmation of sex-specific expression of selected feminine
(pink) and masculine (blue) genes. (C) Adult men exhibit increased expres-
sion of inflammatory and proto-oncogenes, including c-Myc. (D) Top sex-
specific biological function categories are associated with cancer and in-
flammation. *P < 0.05, Student t test.
Fig. 3. PRL inhibits immune induction of MAP3K-dependent pathways in-
cluding PI3K/AKT/mTORC1 by accelerating degradation of trafasome. (A)
PRL constrains mTORC1 members mTOR and 4E-BP1 in parallel with AKT. (B)
MAP3K inhibitor 5(Z)-7-oxozeaenol, but not Ras inhibitor manumycin, mir-
rors PRL in disruption of p38 MAPK, AKT, and NF-κB p65/RelA phosphory-
lation. (C, Upper) Western blot demonstrates that prior PRL accelerates
degradation of IRAK1 following IL-1β challenge in AML12 cells. (Lower)
TRAF6 immunoprecipitation (IP) followed by immunoblot (IB) shows non-
degrading ubiquitination by PRL alone, and accelerated degradation of
IRAK1 and TRAF6 following IL-1β challenge.
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proteins anchor modular signaling complexes (“trafasomes”)
(27) that may incorporate any of several MAP3K (28, 29). Tra-
fasomes rely heavily on context-specific ubiquitination for acti-
vation and signal termination (30). To determine the impact of
PRL on trafasome kinetics, we immunoprecipitated TRAF6
from hepatocytes exposed to PRL or IL-1β. As expected, IL-1β
recruited interleukin-1 receptor-associated kinase 1 (IRAK1) to
the trafasome, resulting in TRAF6 ubiquitination and decreased
total protein consistent with proteasomal degradation or autophagy.
Unexpectedly, we found that PRL alone also recruited IRAK1 to
TRAF6, invoking nondegrading ubiquitination without appre-
ciable loss of either protein (Fig. 3C). Of greatest significance, we
found in PRL-preconditioned hepatocytes that virtually no IRAK1
or TRAF6 could be detected 15 min after IL-1β stimulation, in-
dicating accelerated decay. Our combined results outline a model
whereby PRL recruits IRAK1 to TRAF, resulting in sensitizing
ubiquitination and accelerated degradation of the trafasome fol-
lowing immune stimulation; this in turn terminates downstream
MAP3K-dependent signaling through p38 MAPK, NF-κB,
and PI3K/AKT/mTORC1.
In Vivo Sex-Dependent HCC Is Regulated Above c-Myc. In addition
to immunity, p38 MAPK, NF-κB, and PI3K/AKT/mTORC1
have known associations with cancer in part through induction
of c-Myc (31). Of importance, c-Myc is up-regulated in male-
specific fashion at an early stage in rodent hepatocarcino-
genesis (32). If the present hypothesis is correct and PRL
impedes liver tumorigenesis at the level of the trafasome, then
release of c-Myc from immunoregulatory control should
abolish sex-dependent HCC phenotypes. To test this theory,
we monitored spontaneous tumor development in mice with
constitutive hepatic c-Myc expression under control of the sex-
independent albumin promoter/enhancer (33). To obviate any
potential confounding by proinflammatory gut microbes, mice
were housed in a Helicobacter-free barrier facility (22). Under
these conditions, we found no sex difference in the incidence
or multiplicity of preneoplastic foci of cellular alteration
(FCA) at 3 mo or frank neoplasms at 9 and 15 mo (Fig. 4A).
Functional transgene expression was confirmed by immuno-
histochemistry in 3-mo-old male and female mice (Fig. 4B).
Results of this experiment are consistent with universal liver
tumor promotion through—but sex-dependent regulation above—
the level of c-Myc.
PRL Deficiency Accelerates Liver Tumorigenesis. If PRL constrains
liver tumorigenesis, then PRL deficiency should increase HCC
vulnerability. To test this hypothesis, we inoculated infant
C57BL/6 and strain-matched Prl−/− mice with the liver carcino-
gen diethylnitrosamine (DEN) or vehicle. Compared with WT
controls, DEN-initiated Prl−/− females developed a significantly
higher incidence and multiplicity of liver tumors (Fig. 4C).
Moreover, neoplasms from Prl−/− females exhibited increased
malignancy, as indicated by invasion of adjacent nonneoplastic
tissue and vessels (Fig. 4D). Because factors in addition to PRL
contribute to male HCC vulnerability (i.e., disturbances arising
from growth hormone-mediated liver masculinization) (19), Prl−/−
males still developed a greater tumor burden than females.
Nevertheless, PRL deficiency also increased the multiplicity and
malignancy of HCC in Prl−/− males. Importantly, it has been
shown that Prl−/− female mice maintain circulating E2, albeit at
lower levels than WT mice (34), indicating a requirement for
PRL in hormone-based tumor inhibition. Viewed together,
results from Prl−/− mice indicate that PRL deficiency accelerates
hepatocarcinogenesis in both sexes, but is especially pronounced
in females.
Pharmacologic PRL Mobilization Protects Males from HCC. Estrogen-
based HRT protects postmenopausal women from liver cancer
(3), likely in part through PRL induction. However, HRT is not
a viable strategy for liver cancer prevention in men. To prove in
principle that E2-independent PRL agonism can protect males
from HCC, we initiated tumor-prone C3H/HeN mice with
DEN or vehicle, and administered the PRL-mobilizing dopa-
mine D2 receptor antagonist (α-DRD2) domperidone to a co-
hort of males. Domperidone was withheld until mice had
developed preneoplastic FCA to recapitulate tumor risk pro-
files characteristic of humans with chronic progressive hepatitis
or cirrhosis. As expected, domperidone increased serum PRL
in males to near-female levels (Fig. 5A). All DEN-initiated
untreated males developed HCC, whereas females presented
with FCA and dysplastic nodules only. The multiplicity of
grossly evident dysplastic nodules in domperidone-treated mice
was intermediate between females and untreated males (Fig.
5B). However, with regard to HCC, DEN-initiated males that
received α-DRD2 therapy showed significant protection (22%
incidence vs. 100% in untreated males; P < 0.01) (Fig. 5C).
Moreover, message levels of inflammation-associated gene
products, including SAA3, iNOS, and IL-23α were decreased in
domperidone-treated males to feminine levels, along with tumor-
associated biomarkers c-Myc, Ki-67, and pyruvate kinase M2
(Fig. 5D) (35). Lesions from domperidone-treated males also
more closely resembled female preneoplastic foci with regard to
morphology and oxidative stress biomarkers (e.g., 8-oxoguanine)
than the frank malignancies from untreated males (Fig. 5E).
Combined with studies elsewhere involving the PRL-mobilizing
agents perphenazine and cimetidine (36, 37), our results estab-
lish E2-independent PRL induction as a rational strategy to
prevent HCC.
Fig. 4. Female HCC resistance is PRL-dependent and regulated above c-Myc.
(A) Absence of sex bias in preneoplastic foci and HCC in Alb-Myc(tg)
mice with constitutive hepatic c-Myc expression. (B) Immunohistochemical
confirmation of cytoplasmic and nuclear c-Myc overexpression (dia-
minobenzidine; brown) in transgenic mice of both sexes compared with WT
controls (magnification, 400×). (C) Increased HCC incidence (Upper) and
multiplicity (Lower) in PRL-deficient mice relative to WT controls. (D) DEN-
initiated Prl−/− mice have greater local (arrowheads) and vascular (arrows)
tumor invasion than sex-matched WT controls (magnification, 200×). Data
are expressed as mean ± SEM (n = 9–10 per sex per treatment protocol), *P <
0.05, one-way ANOVA with Tukey posttest.
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Discussion
Hormonally active women are better protected from HCC than
men and postmenopausal women who do not take HRT (3). Our
study implicates a crucial role for prolactin in female HCC re-
sistance. PRL interrupted innate immune pathways in hep-
atocytes mediated by TRAF-dependent IL-1β, LPS/TLR4, and
TNF-α, but not TIR-domain-containing adapter-inducing in-
terferon-β (TRIF)-dependent poly(I:C)/TLR3. We found that
PRL alone invoked sensitizing ubiquitination of a trafasome
comprised of IRAK1, TRAF6, and MAP3K proteins, leading to
accelerated complex degradation following immune stimulation.
This process prevented activation of c-Myc via multiple MAP3K-
dependent pathways, including p38 MAPK, NF-κB, and PI3K/
AKT/mTORC1 (Fig. 6). We hypothesize that PRL function in
liver is mediated predominantly by PRLR-S. Our finding of weak
transcriptional induction by PRL in murine hepatocytes is con-
sistent with the limited impact of PRL on STAT5 signaling in
mouse liver (38). In vivo, circadian/ultradian hormone secretory
patterns regulate gene transcription kinetics (39, 40). It is pos-
sible that ultradian secretion of PRL (7) also influences extra-
nuclear functions of PRLR-S. Delayed onset but persistent
activity of PRL in our model (Fig. S2B) is consistent with the
slow subcellular trafficking and diminuted turnover of ligand-
bound PRLR-S compared with PRLR-L (41). Additional work
will be required to parse the role of different hormones and
receptors in the complex process of human liver carcinogenesis.
Nevertheless, our model reconciles previously disconnected
rodent studies, and introduces a mechanism by which an E2-
responsive pituitary hormone may help prevent HCC.
Our results confirm and extend reports from other groups
showing reduced HCC in mice and rats with PRL mobilization
via pituitary allograft or pharmacologic induction (36, 37).
However, another study reported no impact of PRL receptor
deficiency on DEN-initiated liver carcinogenesis in Prlr−/− mice
(42). There are several potential explanations for this apparent
discrepancy. First, Prl−/− and Prlr−/− mice show numerous bi-
ological differences, including energy metabolism, reproductive
viability, and behavior (43–45). Therefore, PRL ligand and re-
ceptor knockout mice have different phenotypes. Second, Prlr−/−
mice acquire extremely high levels of circulating PRL because of
an absence of negative feedback inhibition (46), which could
result in off-target effects. Finally, the Prlr−/− study limited
analysis to grossly visible liver masses, whereas histopathology
allowed us to distinguish preneoplastic nodules from bona fide
malignancies, which proved to be an important differentiator
(Fig. 4D). Our findings also contrast with a paper that correlated
JAK2 with human HCC, and implied a role for PRL signaling in
tumor progression (47). However, the association between serum
PRL and HCC in patients was correlative only and did not take
into account circulating E2. Additionally, the in vitro experi-
ments relied on HepG2 cells, a cell line derived from hepato-
blastoma and not HCC (48), and which preferentially express
PRLR-L over PRLR-S (Fig. S1B). Finally, the only STAT sen-
sitive to chemical (AG490) or siRNA JAK2 knockdown in their
system was STAT3, not PRLR-associated STAT5. Because
JAK2 is an upstream kinase for STAT3 as well as STAT5 (49), it
is possible that the role of JAK2 in human HCC involves non-
PRLR pathways. Further work will be needed to reconcile our
findings with both studies above.
In summary, we have shown that PRL impedes liver carcino-
genesis by restricting tumor-promoting innate immune responses
within hepatocytes. Important questions remain, including
whether hepatic PRL signaling is strictly PRLR-S–dependent,
how ligand-bound PRLR recruits IRAK1 to the trafasome,
whether TRAF molecules other than TRAF6 are targeted, and
which MAP3K are involved in PRL-sensitive injury responses in
hepatocytes. Furthermore, it is important to note that our model
is not incompatible with studies showing E2-mediated HCC
Fig. 5. PRL-mobilizing DRD2 antagonist domperidone prevents male HCC. (A)
α-DRD2 domperidone increases circulating male PRL to near female levels. (B)
Domperidone in male mice reduces multiplicity of dysplastic nodules to in-
termediate levels between untreated males and females. (C) Domperidone
markedly reduces male HCC incidence (22% vs. 100% in untreated males). (D)
Tumor-associated transcriptional and morphologic biomarkers in α-DRD2–
treated males mirror those of females. (E) Gross and histologic appearance of
DEN-induced lesions in α-DRD2 males approximate those found in females. F,
foci of cellular alteration; H, HCC; 8-oxo-G, 8-oxoguanine; magnification, 100×.
Data are represented as mean ± SEM, *P < 0.05 (n = 9–10 mice per sex per
treatment protocol), one-way ANOVA with Tukey posttest.
Fig. 6. Working model of PRL interruption of TRAF/MAP3K-dependent in-
nate immune activation of the proto-oncogene c-Myc via PI3K/AKT/mTORC1,
p38 MAPK and/or NF-κB in hepatocytes. Inhibitory pathways shown in red,
inflammatory in blue and proliferative in green. Abbreviations: DAMP,
damage-associated molecular pattern; PAMP, pathogen-associated molecu-
lar pattern; PRR, pattern-recognition receptor.
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inhibition through alternative mechanisms (4, 5). Nevertheless,
our preclinical data show that E2-independent PRL mobiliza-
tion, using a generic drug already in human use, is sufficient to
protect males from liver cancer. PRL-targeted therapy may help
prevent HCC in high-risk men and women.
Materials and Methods
C3H/HeN mice were purchased from the National Cancer Institute Frederick
National Laboratory Production Program (Frederick, MD) and C57BL/6 mice
from the Jackson Laboratory. Generation of Albumin-Myc–transgenic [Alb-
Myc(tg)] and Prl−/− mice has been previously described (33, 45). Liver col-
lections, tumor evaluation, histopathology, and molecular evaluations were
performed as described in SI Materials and Methods and according to pre-
viously published techniques (50). Protein and nucleic acid isolation, immu-
noprecipitation, Western blot, and PCR were performed according to the
manufacturers’ protocols. Cell lines except where indicated were obtained
from the University of North Carolina at Chapel Hill (UNC) Lineberger Tissue
Culture Facility and maintained according to ATCC guidelines. Deidentified
human liver biopsies according a protocol approved by the UNC Institutional
Review Board were obtained through the UNC Tissue Procurement Facility.
In vivo sample sizes were projected to yield a study power ≥0.9 using Stat-
Mate software (GraphPad). Statistical evaluations were performed by one-
way ANOVA with Tukey posttest, or Student t test using Prism software
(GraphPad). Animal euthanasia was performed in accordance with the
American Veterinary Medical Association Panel on Euthanasia, and protocols
were approved by the Institutional Animal Care and Use Committees of
UNC and the Massachusetts Institute of Technology. Complete details
are presented in SI Materials and Methods. See Table S6 for all qRT-PCR
primer sequences.
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